je.st
news
Tag: breast cancer
International Breast Cancer Study Group, Breast International Group and Merck Announce Opening of International PANACEA Study of Patients with HER2+ Breast Cancer
2014-12-10 14:45:00| Merck.com - Research & Development News
Dateline City: SAN ANTONIO Collaborative Trial is First to Investigate an Anti-PD-1 Therapy, Pembrolizumab, Combined with Trastuzumab Study to Explore Whether New Approach May Reverse Trastuzumab Resistance in Cancer with Significant Unmet Need SAN ANTONIO--(BUSINESS WIRE)--The International Breast Cancer Study Group (IBCSG), Breast International Group (BIG), and Merck, known as MSD outside the United States and Canada, today announced the opening of the PANACEA study, a global collaborative study exploring a new way to treat HER2+ breast cancer that has become resistant to the current standard of care. Language: English Contact: International Breast Cancer Study GroupLaura Cava Northrop, 617-632-3973press@ibcsg.orgorBreast International GroupCecilia Waldvogel, +41 79 478-0238cecilia.waldvogel@BIGagainstbc.orgorMerckClaire Mulhearn, 908-236-1118claire.mulhearn@merck.com Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: international
group
study
opening
Data Investigating KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast Cancer Presented at 2014 San Antonio Breast Cancer Symposium
2014-12-10 14:30:00| Merck.com - Corporate News
Dateline City: SAN ANTONIO 18.5 Percent Overall Response Rate Observed in KEYTRUDA-Treated Patients with This Aggressive Form of Breast Cancer Phase 2 Study Planned for the First Half of 2015 (KEYNOTE-086) SAN ANTONIO--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating an overall response rate of 18.5 percent with KEYTRUDA, the companys anti-PD-1 therapy, as assessed by RECIST v1.1, central review (n=5/27), in PD-L1 positive, advanced triple-negative breast cancer one of the most aggressive forms of breast cancer. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558Claire Mulhearn, (908) 236-1118orInvestor:Joseph Romanelli, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
san
presented
Changes to late-stage breast cancer trial sends shares of Celldex plunging
2014-11-06 01:48:08| Biotech - Topix.net
It wasn't the financial picture at Celldex Therapeutics that sent investors running today. Rather, it was the news that a trial of one its two lead cancer drugs will last longer than hoped that sent its shares down 20 percent as of 2 p.m. today.
Tags: trial
cancer
shares
breast
Kroger Customers Raise More Than $674,000 to Support Breast Cancer Awareness, Treatment and Research
2014-11-04 18:21:00| Grocery - Topix.net
Kroger customers and associates throughout the Atlanta Division donated more than $461,000 to Susan G. Komen for the Cure and more than $213,000 to Kroger's "Sharing Courage" campaign, for a total of $674,000 - surpassing the Division's $450,000 goal by more than $224,000. The multi-faceted campaign ran from Oct. 5 - Nov. 1, and gave customers the opportunity to purchase pink paper ribbons for $1 at Kroger checkout.
Tags: support
research
treatment
customers
LSU Health New Orleans receives grant to support young breast cancer survivors in the Gulf South
2014-11-04 16:13:58| Biotech - Topix.net
The LSU Health New Orleans School of Public Health has been awarded a $2.2 million grant to increase the availability of health information and support services for young breast cancer survivors in the Gulf South. The funding, awarded by the Centers for Disease Control and Prevention over five years, will support the development and implementation of strategic and integrated multi-media health education and awareness campaigns to address their health information needs.
Tags: support
health
south
young
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] next »